JP2020518287A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518287A5 JP2020518287A5 JP2020511867A JP2020511867A JP2020518287A5 JP 2020518287 A5 JP2020518287 A5 JP 2020518287A5 JP 2020511867 A JP2020511867 A JP 2020511867A JP 2020511867 A JP2020511867 A JP 2020511867A JP 2020518287 A5 JP2020518287 A5 JP 2020518287A5
- Authority
- JP
- Japan
- Prior art keywords
- modified fgf
- polypeptide
- recombinant modified
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 19
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 2
- 201000007717 corneal ulcer Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000028006 Corneal injury Diseases 0.000 claims 1
- 208000020564 Eye injury Diseases 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000002159 anterior chamber Anatomy 0.000 claims 1
- 238000005422 blasting Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000871 endothelium corneal Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 102220231685 rs1064797227 Human genes 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024075396A JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502540P | 2017-05-05 | 2017-05-05 | |
| US201762502529P | 2017-05-05 | 2017-05-05 | |
| US62/502,540 | 2017-05-05 | ||
| US62/502,529 | 2017-05-05 | ||
| US201762584624P | 2017-11-10 | 2017-11-10 | |
| US62/584,624 | 2017-11-10 | ||
| PCT/US2018/031189 WO2018204847A2 (en) | 2017-05-05 | 2018-05-04 | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075396A Division JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518287A JP2020518287A (ja) | 2020-06-25 |
| JP2020518287A5 true JP2020518287A5 (https=) | 2021-06-17 |
Family
ID=64016756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511867A Pending JP2020518287A (ja) | 2017-05-05 | 2018-05-04 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
| JP2024075396A Pending JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024075396A Pending JP2024112824A (ja) | 2017-05-05 | 2024-05-07 | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11479591B2 (https=) |
| EP (2) | EP4621067A3 (https=) |
| JP (2) | JP2020518287A (https=) |
| KR (1) | KR20200078425A (https=) |
| CN (1) | CN111148755A (https=) |
| AU (1) | AU2018261021B2 (https=) |
| BR (1) | BR112019023260A2 (https=) |
| CA (1) | CA3062473A1 (https=) |
| DK (1) | DK3619324T3 (https=) |
| ES (1) | ES3041527T3 (https=) |
| MX (1) | MX2019013210A (https=) |
| WO (1) | WO2018204847A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019013210A (es) | 2017-05-05 | 2020-07-20 | Trefoil Therapeutics Inc | Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. |
| WO2021261946A1 (ko) | 2020-06-26 | 2021-12-30 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
| CN116710568A (zh) * | 2020-06-26 | 2023-09-05 | 特里福伊尔治疗公司 | 重组修饰成纤维细胞生长因子及其治疗用途 |
| EP4574211A3 (en) * | 2021-05-14 | 2025-09-10 | Claris Biotherapeutics, Inc. | Compositions of growth factor for the treatment of eye disease |
| CN113289005B (zh) * | 2021-07-06 | 2022-05-31 | 温州医科大学 | rhFGF-21在制备治疗干眼症药物中的应用 |
| WO2023019218A1 (en) * | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
| US12357843B2 (en) | 2022-03-25 | 2025-07-15 | Cutera, Inc. | Methods of skin treatment with laser light |
| CN115177717B (zh) * | 2022-08-31 | 2026-02-06 | 贵州医科大学附属医院 | 一种治疗眼表及角膜上皮疾病的药物 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022758A (en) | 1973-06-19 | 1977-05-10 | Ab Kabi | Isolation of coagulation factors I and VIII from biological material |
| US5552528A (en) * | 1986-03-03 | 1996-09-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bovine b-endothelial cell growth factor |
| US5312911A (en) | 1987-10-22 | 1994-05-17 | Merck & Co., Inc. | Cysteine-modified acidic fibroblast growth factor |
| US5223483A (en) | 1987-10-22 | 1993-06-29 | Merck & Co., Inc. | Cysteine-modified acidic fibroblast growth factor |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5510329A (en) | 1988-04-26 | 1996-04-23 | Ramot University For Applied Research And Industrial Development Ltd. | Preparations for the treatment of eyes |
| GB2223496B (en) * | 1988-08-08 | 1992-05-27 | British Bio Technology | Synthetic gene encoding mature human acid fibroblast growth factor |
| US6780837B1 (en) | 1989-08-30 | 2004-08-24 | The Regents Of The University Of California | Prevention of retinal injury and degeneration by specific factors |
| US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5624893A (en) | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US20040071787A1 (en) | 1996-05-01 | 2004-04-15 | Maine Medical Center Research Institute | Pharmacologic, therapeutic and diagnostic regulation of FGF-1 export |
| US20010006939A1 (en) | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| WO1999055861A2 (en) | 1998-04-28 | 1999-11-04 | Eisai Co., Ltd. | Fibroblast growth factor mutein compositions and methods of use therefor |
| WO2001038357A2 (en) * | 1999-11-22 | 2001-05-31 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
| US20020001825A1 (en) | 2000-03-31 | 2002-01-03 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
| JP2004517607A (ja) * | 2000-08-15 | 2004-06-17 | ファージ バイオテクノロジー コーポレイション | 生物学的に活性なヒト酸性線維芽細胞成長因子の産生方法および血管新生の促進におけるその使用 |
| US20100254900A1 (en) | 2002-03-18 | 2010-10-07 | Campbell Phil G | Biocompatible polymers and Methods of use |
| WO2005048942A2 (en) | 2003-11-13 | 2005-06-02 | Pharmacia Corporation | Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
| EP2270163A1 (en) | 2003-12-10 | 2011-01-05 | Eli Lilly and Company | Muteins of fibroblast growth factor 21 |
| EP1634877B1 (en) * | 2004-08-17 | 2011-06-22 | Simpson Biotech Co., Ltd. | Mixture and compounds from mycelia of antrodia camphorata and use thereof |
| US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| US20090156477A1 (en) | 2005-03-29 | 2009-06-18 | Massachusetts Institute Of Technology | Compositions and Methods for Regulating Inflammatory Responses |
| US7767656B2 (en) | 2005-04-25 | 2010-08-03 | Molly S Shoichet | Blends of temperature sensitive and anionic polymers for drug delivery |
| CN100334114C (zh) | 2005-07-22 | 2007-08-29 | 彭隽 | 一种新型融合蛋白及其制备 |
| AU2007240732B2 (en) | 2006-04-21 | 2013-07-04 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| AR062069A1 (es) | 2006-07-14 | 2008-10-15 | Genentech Inc | Replegado de proteinas recombinantes |
| EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| US7776825B1 (en) | 2006-11-09 | 2010-08-17 | Florida State University Research Foundation, Incorporated | Mutant polypeptides of fibroblast growth factor 1 |
| US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
| KR20200075044A (ko) * | 2008-01-22 | 2020-06-25 | 아라임 파마슈티칼즈, 인크. | 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110224404A1 (en) | 2010-03-11 | 2011-09-15 | Florida State University Research Foundation | Method for development of a peptide building block useful for de novo protein design |
| WO2011130729A2 (en) | 2010-04-16 | 2011-10-20 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf |
| US9029113B2 (en) | 2011-03-11 | 2015-05-12 | Kaneka Corporation | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same |
| WO2013036708A2 (en) | 2011-09-07 | 2013-03-14 | The Regents Of The University Of California | Compositions and methods for tissue repair with extracellular matrices |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| US20140045751A1 (en) | 2012-08-10 | 2014-02-13 | Florida State University Research Foundation | Recombinant human fibroblast growth factor-1 as a novel therapeutic for ischemic diseases and methods thereof |
| CN113679699B (zh) | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| US9714291B2 (en) | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
| US20150253308A1 (en) * | 2013-05-03 | 2015-09-10 | Orasis | Compositions and methods of treating glaucoma |
| WO2015048188A2 (en) | 2013-09-25 | 2015-04-02 | Trefoil Therapeutics, Llc | Modified fibroblast growth factors for the treatment of ocular disorders |
| TWI634898B (zh) * | 2013-10-07 | 2018-09-11 | 雅祥生技醫藥股份有限公司 | 經修飾之人類酸性纖維母細胞生長因子及其組合物 |
| US20150104494A1 (en) * | 2013-10-11 | 2015-04-16 | Ohio State Innovation Foundation | Methods for repair of ear canal tissue defects |
| AU2014340241B2 (en) | 2013-10-21 | 2018-11-01 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
| WO2015061351A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| WO2015198175A1 (en) * | 2014-06-27 | 2015-12-30 | Florida State University Research Foundation, Inc. | Design of fgf-1 mutants to effectively eliminate reactive cysteine residues |
| AU2016252426A1 (en) | 2015-04-20 | 2017-11-23 | Salk Institute For Biological Studies | Fibroblast growth factor (FGF) 1 mutants and methods of use to reduce blood glucose |
| EP3285798A4 (en) | 2015-04-20 | 2018-12-05 | Salk Institute for Biological Studies | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
| WO2017026156A1 (ja) * | 2015-08-13 | 2017-02-16 | 富士フイルム株式会社 | 多能性幹細胞の培養方法、培養容器の製造方法、培養容器、及び細胞培養用の足場材料 |
| EP3368059A4 (en) | 2015-10-30 | 2019-03-27 | Salk Institute for Biological Studies | TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE |
| CN108718522A (zh) | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| WO2017172525A2 (en) | 2016-03-28 | 2017-10-05 | Trefoil Therapeutics, Llc | Modified fibroblast growth factors and uses thereof |
| MX2019013210A (es) | 2017-05-05 | 2020-07-20 | Trefoil Therapeutics Inc | Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. |
| CN111315886A (zh) | 2017-06-23 | 2020-06-19 | 珠海亿胜生物制药有限公司 | 重组人碱性成纤维细胞生长因子(rh-bFGF)以及包含rh-bFGF的药物组合物 |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| CN116710568A (zh) | 2020-06-26 | 2023-09-05 | 特里福伊尔治疗公司 | 重组修饰成纤维细胞生长因子及其治疗用途 |
| WO2023019218A1 (en) | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
| WO2023043743A1 (en) | 2021-09-14 | 2023-03-23 | Trefoil Therapeutics, Inc. | Methods of treatment using modified fgf-1 polypeptides |
-
2018
- 2018-05-04 MX MX2019013210A patent/MX2019013210A/es unknown
- 2018-05-04 US US16/611,182 patent/US11479591B2/en active Active
- 2018-05-04 DK DK18794391.5T patent/DK3619324T3/da active
- 2018-05-04 CN CN201880044863.5A patent/CN111148755A/zh active Pending
- 2018-05-04 WO PCT/US2018/031189 patent/WO2018204847A2/en not_active Ceased
- 2018-05-04 BR BR112019023260-5A patent/BR112019023260A2/pt not_active IP Right Cessation
- 2018-05-04 EP EP25181506.4A patent/EP4621067A3/en active Pending
- 2018-05-04 AU AU2018261021A patent/AU2018261021B2/en active Active
- 2018-05-04 CA CA3062473A patent/CA3062473A1/en active Pending
- 2018-05-04 JP JP2020511867A patent/JP2020518287A/ja active Pending
- 2018-05-04 EP EP18794391.5A patent/EP3619324B1/en active Active
- 2018-05-04 ES ES18794391T patent/ES3041527T3/es active Active
- 2018-05-04 KR KR1020197035895A patent/KR20200078425A/ko not_active Ceased
-
2022
- 2022-09-07 US US17/939,238 patent/US12600756B2/en active Active
-
2024
- 2024-05-07 JP JP2024075396A patent/JP2024112824A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518287A5 (https=) | ||
| JP4310588B2 (ja) | 新規ペプチドおよびその医薬用途 | |
| JP2019533722A5 (https=) | ||
| JP6472438B2 (ja) | アンジオテンシンペプチドによる眼外傷の修復促進 | |
| JP2024112824A (ja) | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 | |
| KR20220079860A (ko) | 신규 펩티드 | |
| JP2020183391A (ja) | チモシンベータ４を含む眼科用製剤の製造方法 | |
| JP2018502860A5 (https=) | ||
| JP4249025B2 (ja) | ドライアイおよびドライアイを伴う疾病の治療剤 | |
| JP2009500045A5 (https=) | ||
| US20170209498A1 (en) | Methods for treating ocular contusion and blunt injury and traumatic injury of the optic nerve | |
| KR101838759B1 (ko) | 점안제 | |
| RU2018140501A (ru) | Пэгилированные биологически активные пептиды и их применение | |
| JP2019522046A5 (https=) | ||
| JP2019516675A5 (https=) | ||
| JP2022538903A5 (https=) | ||
| JP2019519466A5 (https=) | ||
| JPWO2005102375A1 (ja) | Ｐａｃａｐおよびその誘導体を含有する角膜神経突起形成促進剤 | |
| US10501511B2 (en) | Low molecular polypeptide for preventing and treating inflammation and use thereof | |
| CN105017406B (zh) | 一类新的具有神经保护功能的多肽 | |
| JP7832745B2 (ja) | 網膜色素上皮細胞の保護剤 | |
| US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
| CN110092816B (zh) | 预防和治疗纤维化的小分子多肽及其应用 | |
| JP2023517459A (ja) | 眼科用医薬組成物及びその使用 | |
| JP2016519110A5 (https=) |